Physician profile
Patrick Grey Gillette
NPI 1083202147
$8,742.97
in general payments reported to CMS, 2019-2025
35 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,336 · 2023: $3,009 · 2024: $3,005 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,390 · Education: $16.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,390.35 |
| Education | $16.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,001.74 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $784.78 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Supernus Pharmaceuticals, INC. | $669.02 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $553.47 | 2023-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $530.22 | 2022-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $515.97 | 2022-2025 | Caplyta |
| Bausch Health US, LLC | $509.61 | 2022-2025 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $484.47 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $463.60 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Mycite |
| Neurocrine Biosciences, INC. | $438.26 | 2022-2025 | Ingrezza |
| Tris Pharma INC | $345.47 | 2022-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $324.28 | 2022-2024 | Spravato |
| Corium, LLC | $321.13 | 2022-2025 | Azstarys |
| Alkermes, INC. | $276.64 | 2023-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $242.67 | 2022-2025 | Trintellix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $222.38 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Idorsia Pharmaceuticals US INC | $193.81 | 2023-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $172.26 | 2023-2025 | Fanapt, Hetlioz |
| Collegium Pharmaceutical, INC. | $146.82 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $101.86 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $95.05 | 2023 | Belsomra |
| Noven Therapeutics, LLC | $83.96 | 2023-2024 | Xelstrym, Secuado |
| Almatica Pharma LLC | $59.88 | 2023-2024 | Loreev Xr |
| Eisai INC. | $30.29 | 2023-2024 | |
| Avion Pharmaceuticals | $19.38 | 2023 | Methylphenidate Hydrochloride |
| Livanova USA, INC. | $19.25 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Sunovion Pharmaceuticals INC. | $17.08 | 2022 | |
| Lilly USA, LLC | $16.95 | 2022 | |
| Vertical Pharmaceuticals, LLC | $16.20 | 2024 | Relexxii |
| Biohaven Pharmaceutical Holding Company LTD. | $15.33 | 2022 | |
| Pfizer INC. | $15.22 | 2023 | |
| Amgen INC. | $14.95 | 2022 | |
| Janssen Scientific Affairs, LLC | $14.40 | 2022 | |
| Acadia Pharmaceuticals INC | $13.75 | 2025 | Nuplazid |
| Brainsway USA INC | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gillette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.